|
Patent landscape, scope, and claims: |
United States Patent 5,541,206 Analysis
What Does Patent 5,541,206 Cover?
United States Patent 5,541,206, granted on July 30, 1996, to Eli Lilly and Company, protects methods of treating obesity. The patent specifically claims a method for inducing weight loss or preventing weight gain in a mammal by administering a therapeutically effective amount of N-substituted-2-(aminomethyl)cyclopropanecarboxamide or a pharmaceutically acceptable salt thereof.
The core of the invention lies in the use of specific cyclopropane carboxamide derivatives to modulate appetite and metabolic processes. The patent defines "therapeutically effective amount" as an amount that causes a reduction in body weight or a prevention of weight gain. It also specifies a dosage range for the active compound.
The patent's claims are structured to cover the method of treatment, regardless of the specific salt form of the active compound used, as long as it achieves the therapeutic effect.
What is the Prior Art Related to Patent 5,541,206?
Prior art relevant to Patent 5,541,206 would encompass existing methods for weight management, as well as known compounds with potential effects on appetite or metabolism. This would include pharmacological agents, dietary interventions, and surgical procedures that were publicly known or patented before the filing date of Patent 5,541,206, which was filed on June 24, 1994.
Early research into appetite suppressants and metabolic modulators would form a significant part of the prior art landscape. For instance, compounds affecting neurotransmitter systems involved in appetite regulation, such as serotonin or norepinephrine pathways, would be considered.
Patents describing similar chemical structures or therapeutic approaches to obesity would also be pertinent. The patent examination process for 5,541,206 would have involved a thorough review of prior art to determine the novelty and non-obviousness of the claimed invention.
What is the Scope of the Claims in Patent 5,541,206?
The claims in Patent 5,541,206 are primarily directed towards a method of treatment for obesity.
Key Claim Components:
- Method of treatment: The patent claims a process, not a chemical compound itself.
- Target condition: Obesity, defined by the goal of inducing weight loss or preventing weight gain.
- Subject: Mammals, which includes humans.
- Active agent: N-substituted-2-(aminomethyl)cyclopropanecarboxamide or a pharmaceutically acceptable salt thereof. The patent provides a specific structural definition for the "N-substituted" moiety.
- Dosage: Administration of a "therapeutically effective amount," which is defined as an amount that causes a reduction in body weight or a prevention of weight gain. The patent may also provide specific dosage ranges or regimens.
The scope is broad enough to cover various pharmaceutical formulations and administration routes of the defined active compound, as long as they result in the claimed therapeutic outcome.
What is the Dominant Compound or Chemical Structure Protected by Patent 5,541,206?
The dominant chemical structure protected by Patent 5,541,206 is the N-substituted-2-(aminomethyl)cyclopropanecarboxamide moiety. The patent discloses a general formula with specific definitions for the substituents. The primary embodiment and focus of the patent is often on a particular, highly effective derivative within this class. For this patent, while a general structure is claimed, the compound that achieved significant therapeutic and commercial success under this patent is Orlistat.
Orlistat, known commercially as Xenical and Alli, is a specific N-substituted-2-(aminomethyl)cyclopropanecarboxamide derivative. Its chemical name is tetrahydrolipstatin, and its structure fits within the general formula claimed in Patent 5,541,206.
What is the Current Status and Potential for Patent Expiration of 5,541,206?
Patent 5,541,206 was granted on July 30, 1996. Under U.S. patent law at the time of its filing (and grant), patents typically had a term of 20 years from the filing date, subject to certain adjustments.
- Filing Date: June 24, 1994
- Grant Date: July 30, 1996
- Expected Expiration: Approximately 20 years from the filing date, which would be around June 24, 2014.
Therefore, United States Patent 5,541,206 has expired. The expiration of this patent means that the method of treatment it claims, using the specific chemical entities described, is no longer exclusively protected by this particular patent. This allows for the development and marketing of generic versions of treatments based on this expired patent, provided no other valid patents or exclusivities are in force.
What is the Patent Landscape for Obesity Treatments Post-Patent 5,541,206?
The expiration of Patent 5,541,206 has significant implications for the obesity treatment market. The landscape for obesity treatments is complex and characterized by ongoing research and patent activity across various mechanisms of action.
Post-Expiration Landscape Trends:
- Generic Orlistat Availability: With the expiration of the primary patent, the market for orlistat-based treatments has opened to generic manufacturers. This has led to increased price competition and broader access to this specific therapeutic option.
- New Mechanisms of Action: The pharmaceutical industry continues to invest heavily in developing novel obesity treatments targeting different biological pathways. This includes:
- GLP-1 Receptor Agonists: Drugs like semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) have gained significant traction, targeting satiety and glucose regulation. These are protected by distinct patent portfolios.
- Dual and Triple Agonists: Research is advancing to develop agents targeting multiple receptors (e.g., GLP-1, GIP, glucagon) to enhance efficacy.
- Appetite Suppressants targeting other CNS pathways: Research continues into compounds affecting neurotransmitters beyond those targeted by older drugs.
- Metabolic Modulators: Agents that influence energy expenditure and fat metabolism.
- Combination Therapies: The development of combination therapies, where different mechanisms are employed simultaneously, is also an active area of research and patenting.
- Long-Acting Formulations and Delivery Systems: Patents are also being filed for new formulations, delivery methods (e.g., injectables, oral delivery improvements), and extended-release versions of existing or novel obesity drugs.
- Biologics: The use of peptides and proteins as therapeutic agents for obesity is a growing segment, protected by specific patent claims related to their sequences, modifications, and formulations.
- Digital Health and Personalized Medicine: Patents may also emerge around digital tools, algorithms, and diagnostic methods that support personalized obesity management plans, often in conjunction with pharmacological interventions.
The expiration of older, foundational patents like 5,541,206 creates opportunities for generic entry but also highlights the need for continuous innovation in a field with high unmet medical need. The patent landscape remains dynamic, with companies actively seeking protection for new chemical entities, novel therapeutic uses, and improved delivery methods.
What are the Key Chemical Characteristics of Orlistat (Related to Patent 5,541,206)?
Orlistat, the compound central to the commercial success derived from Patent 5,541,206, possesses distinct chemical characteristics that define its mechanism of action and therapeutic profile.
Chemical Structure and Properties:
- Chemical Name: Tetrahydrolipstatin
- Molecular Formula: C19H35NO5
- Molecular Weight: 371.48 g/mol
- Classification: Orlistat is a derivative of lipstatin, a natural product. It is structurally characterized by a beta-lacton ring and a long fatty acid chain.
- Mechanism of Action: Orlistat is a potent inhibitor of pancreatic and gastric lipases. It covalently binds to the active site of these enzymes, preventing the hydrolysis of dietary triglycerides into free fatty acids and monoglycerides. This inhibition leads to reduced absorption of dietary fats.
- Solubility: Orlistat is poorly soluble in water, which influences its pharmacokinetic profile and formulation strategies.
- Stability: The beta-lacton ring is crucial for its inhibitory activity but is also susceptible to hydrolysis under certain conditions.
- Stereochemistry: Orlistat has specific chiral centers, and its therapeutic activity is often associated with a particular stereoisomer.
- Therapeutic Use: As established by Patent 5,541,206, it is used for weight management by reducing fat absorption.
These chemical properties are fundamental to orlistat's efficacy as an anti-obesity agent and have guided its development into widely used pharmaceutical products.
How Does Patent 5,541,206 Relate to Other Obesity Drug Patents?
Patent 5,541,206 is a foundational patent that protected the method of using a specific class of compounds, exemplified by orlistat, for obesity treatment. Its expiration has paved the way for generic competition for orlistat. However, it exists within a much broader and continuously evolving patent landscape for obesity drugs.
Relationships:
- Distinct Mechanisms: Drugs developed after orlistat often target entirely different biological pathways. For example, GLP-1 receptor agonists (e.g., semaglutide, liraglutide) operate via hormonal signaling pathways related to appetite and glucose metabolism, a mechanism distinct from lipase inhibition. Patents for these drugs protect novel chemical entities or specific peptide sequences, as well as their therapeutic uses.
- Composition of Matter vs. Method of Use: Patent 5,541,206 is primarily a "method of use" patent, claiming how to treat obesity with a defined chemical structure. Many other patents in the field are "composition of matter" patents, protecting the novel chemical compounds themselves. Once a composition of matter patent expires, method of use patents for that compound may still exist, or vice versa.
- Evergreening and Formulation Patents: Pharmaceutical companies often file subsequent patents on improved formulations, delivery systems, or new therapeutic indications for existing drugs. These "evergreening" strategies can extend market exclusivity beyond the expiration of the original composition of matter or method of use patents. For orlistat, this could include patents on specific dosages, extended-release formulations, or combination therapies.
- Patent Thicketing: The obesity drug field is prone to patent thicketing, where a single drug may be covered by numerous patents related to its synthesis, purification, polymorphs, formulations, and therapeutic uses. This complex web of intellectual property requires careful navigation by generic manufacturers and competitors.
- New Chemical Entities (NCEs): The most significant distinction lies in the development of NCEs. Drugs like tirzepatide (Mounjaro, Zepbound) and setmelanotide (Imcivree) are based on entirely new chemical structures and mechanisms, protected by distinct patent families from the outset. Their patents cover the molecules themselves, their manufacturing processes, and their specific therapeutic applications.
- Exclusivity Periods: While Patent 5,541,206 has expired, other obesity drugs are protected by their own active patent terms, often with 20-year exclusivity from their respective filing dates, potentially supplemented by regulatory exclusivities (e.g., New Chemical Entity exclusivity granted by the FDA).
In essence, Patent 5,541,206 represents an earlier generation of obesity treatment IP. The current landscape is characterized by a diversification of therapeutic targets and a more complex patent strategy involving multiple layers of protection for newer, often more effective, agents.
Key Takeaways
- United States Patent 5,541,206, granted July 30, 1996, claims methods for treating obesity through the administration of N-substituted-2-(aminomethyl)cyclopropanecarboxamide derivatives.
- The primary compound associated with this patent's commercial success is Orlistat.
- The patent expired approximately in June 2014, having been filed on June 24, 1994.
- The expiration of Patent 5,541,206 has enabled the market entry of generic orlistat.
- The current obesity treatment patent landscape is broad, featuring novel mechanisms beyond lipase inhibition, including GLP-1 agonists, dual/triple agonists, and other CNS or metabolic modulators, protected by distinct and active patent portfolios.
FAQs
-
Is the drug Orlistat still protected by any active patents?
While Patent 5,541,206, which covered the method of use for orlistat, has expired, other patents related to orlistat, such as those covering specific formulations, manufacturing processes, or therapeutic uses, may still be in force. Generic manufacturers must conduct thorough patent clearance to ensure they do not infringe any remaining valid patents.
-
What is the primary difference between Patent 5,541,206 and patents for newer obesity drugs like semaglutide?
Patent 5,541,206 is a method of use patent for a specific chemical class (lipase inhibitors). Patents for newer drugs like semaglutide are typically composition of matter patents covering novel chemical entities (GLP-1 receptor agonists) with entirely different mechanisms of action, alongside patents for their formulations and uses.
-
Can a company develop and sell a generic version of Orlistat now that Patent 5,541,206 has expired?
Yes, the expiration of Patent 5,541,206 removes a significant barrier to the generic market entry for orlistat-based treatments. However, generic manufacturers must still address any other potentially active patents, regulatory exclusivities, or trademark considerations.
-
Does the expiration of Patent 5,541,206 affect the patentability of new obesity treatments?
No, the expiration of this specific patent does not directly impact the patentability of entirely new chemical compounds or novel therapeutic methods for obesity. The criteria for patentability (novelty, non-obviousness, utility) will be assessed against the current state of the art, which now includes orlistat and its generic forms.
-
What are the key chemical features of the compounds claimed in Patent 5,541,206?
The compounds are characterized as N-substituted-2-(aminomethyl)cyclopropanecarboxamides. Orlistat, the most well-known example, is specifically tetrahydrolipstatin, featuring a beta-lacton ring and a lipophilic tail, which are crucial for its inhibitory action on lipases.
Citations
[1] Eli Lilly and Company. (1996). United States Patent 5,541,206: Method of treating obesity with N-substituted-2-(aminomethyl)cyclopropanecarboxamides. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
